Cipher Pharmaceuticals
6560 Kennedy Road
Mississauga
Ontario
L5T 2X4
Canada
Tel: 905-565-0043
Fax: 905-565-1776
230 articles with Cipher Pharmaceuticals
-
Notice of Cipher Pharmaceuticals Q1 2019 Conference Call
5/1/2019
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Nadine Jutlah, Interim Chief Financial Officer.
-
Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors
3/26/2019
Cipher Pharmaceuticals Inc. today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.
-
Cipher Pharmaceuticals Announces Change to Management Team
3/20/2019
Cipher Pharmaceuticals Inc. announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities.
-
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
3/19/2019
Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and twelve months ended December 31st, 2018.
-
Notice of Cipher Pharmaceuticals Q4 2018 Conference Call
3/15/2019
Cipher Pharmaceuticals Inc. announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019.
-
Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
12/18/2018
Cipher Pharmaceuticals Inc. announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada.
-
Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada
12/17/2018
Cipher Pharmaceuticals (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ("Synergy") in February 2018.
-
Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018
12/5/2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET.
-
Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations
12/4/2018
Cipher Pharmaceuticals Inc. today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations.
-
Cipher Pharmaceuticals Reports Q3 2018 Results
11/7/2018
Canadian product revenue increased 27%
-
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
-
Notice of Cipher Pharmaceuticals Q3 2018 Conference Call
10/24/2018
Cipher Pharmaceuticals Inc. today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018.
-
Cipher Pharmaceuticals Announces Canadian Launch of Brinavess (vernakalant hydrochloride)
10/24/2018
Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibrillation
-
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
9/18/2018
Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market
-
Cipher Pharmaceuticals Reports Q2 2018 Results
8/10/2018
Canadian product revenue increased 33%
-
Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica
7/30/2018
New portfolio royalty extends through December 2024
-
Notice of Cipher Pharmaceuticals Q2 2018 Conference Call
7/23/2018
Cipher Pharmaceuticals Inc. announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018.
-
Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs
6/6/2018
Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.
-
Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.
5/16/2018
Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. was completed.
-
Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma
5/15/2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced acquisition of Cardiome Pharma Corp.